Drug Interactions between Fosteum and progesterone topical
This report displays the potential drug interactions for the following 2 drugs:
- Fosteum (cholecalciferol/genistein/zinc glycinate)
- progesterone topical
Interactions between your drugs
progesterone topical genistein
Applies to: progesterone topical and Fosteum (cholecalciferol / genistein / zinc glycinate)
Long term concomitant use of transdermal progesterone and soy milk isoflavones may result in bone-loss. One 2-year randomized, placebo controlled study involving postmenopausal women with osteoporosis or having at least 3 risk factors for osteoporosis compared the effects of soy milk (equivalent to 76 mg isoflavones/day, n=23), transdermal progesterone (equivalent to 25.7 mg/day, n=22), soy milk + transdermal progesterone (n=22) or placebo (n=22). They found that the combination group (soy milk + transdermal progesterone) had higher bone-loss than either treatment alone, but not as pronounced as in the placebo group. Until more information is available, caution and bone-loss monitoring are recommended if transdermal progesterone is administered together with soy isoflavones over extended periods of time in postmenopausal women with osteoporosis or at risk of developing osteoporosis.
References (2)
- Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
- Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T (2004) "Soymilk or progesterone for prevention of bone loss-a 2 year randomized, placebo-controlled trial." Eur J Nutr, 43, p. 246-57
Drug and food interactions
cholecalciferol food
Applies to: Fosteum (cholecalciferol / genistein / zinc glycinate)
MONITOR: Additive effects and possible toxicity (e.g., hypercalcemia, hypercalciuria, and/or hyperphosphatemia) may occur when patients using vitamin D and/or vitamin D analogs ingest a diet high in vitamin D, calcium, and/or phosphorus. The biologically active forms of vitamin D stimulate intestinal absorption of calcium and phosphorus. This may be helpful in patients with hypocalcemia and/or hypophosphatemia. However, sudden increases in calcium or phosphorus consumption due to dietary changes could precipitate hypercalcemia and/or hyperphosphatemia. Patients with certain disease states, such as impaired renal function, may be more susceptible to toxic side effects like ectopic calcification. On the other hand, if dietary calcium is inadequate for the body's needs, the active form of vitamin D will stimulate osteoclasts to pull calcium from the bones. This may be detrimental in a patient with reduced bone density.
MANAGEMENT: Given the narrow therapeutic index of vitamin D and vitamin D analogs, the amounts of calcium, phosphorus, and vitamin D present in the patient's diet may need to be taken into consideration. Specific dietary guidance should be discussed with the patient and regular lab work should be monitored as indicated. Calcium, phosphorus, and vitamin D levels should be kept within the desired ranges, which may differ depending on the patient's condition. Patients should also be counseled on the signs and symptoms of hypervitaminosis D, hypercalcemia, and/or hyperphosphatemia.
References (10)
- (2023) "Product Information. Drisdol (ergocalciferol)." Validus Pharmaceuticals LLC
- (2024) "Product Information. Fultium-D3 (colecalciferol)." Internis Pharmaceuticals Ltd
- (2024) "Product Information. Ostelin Specialist Range Vitamin D (colecalciferol)." Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare
- (2021) "Product Information. Rocaltrol (calcitriol)." Atnahs Pharma UK Ltd
- (2019) "Product Information. Calcitriol (calcitriol)." Strides Pharma Inc.
- (2024) "Product Information. Calcitriol (GenRx) (calcitriol)." Apotex Pty Ltd
- (2022) "Product Information. Ergocalciferol (ergocalciferol)." RPH Pharmaceuticals AB
- (2020) "Product Information. Sandoz D (cholecalciferol)." Sandoz Canada Incorporated
- Fischer V, Haffner-Luntzer M, Prystaz K, et al. (2024) Calcium and vitamin-D deficiency marginally impairs fracture healing but aggravates posttraumatic bone loss in osteoporotic mice. https://www.nature.com/articles/s41598-017-07511-2
- National Institutes of Health Office of Dietary Supplements (2024) Vitamin D https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/#h37
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.